Our Science – Gottesman Website
Michael M. Gottesman, M.D.
Selected Publications |
 |
| 1)
Pouliot LM, Shen DW, Suzuki T, Hall MD, Gottesman MM. Contributions of microRNA dysregulation to cisplatin resistance in adenocarcinoma cells. Exp. Cell Res. 319: 566-74, 2013. [Journal] |
|
| 2)
Chakraborty AR, Robey RW, Luchenko VL, Zhan Z, Piekarz RL, Gillet J, Kossenkov AV, Wilkerson J, Showe LC, Gottesman MM, Collie NL, Bates SE. MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with a MEK inhibitor. Blood. [Epub ahead of print], 2013. [Journal] |
|
| 3)
Salari R, Kimchi-Sarfaty C, Gottesman MM, Przytycka TM. Sensitive measurement of single-nucleotide polymorphism-induced changes of RNA conformation: application to disease studies. Nucleic Acids Res. 41: 44-53, 2013. [Journal] |
|
| 4)
Gillet JP, Varma S, Gottesman MM. The clinical relevance of cancer cell lines. J. Natl. Cancer Inst. 105: 452-8, 2013. [Journal] |
|
| 5)
Hochman J, Shen D, Gottesman MM, Chan C. Anti-LFA-1 antibodies enhance metastasis of ocular lymphoma to the brain and contralateral eye. Clin. Exp. Metastasis. [Epub ahead of print], 2012. [Journal] |
|
| 6)
Shen DW, Pouliot LM, Hall MD, Gottesman MM. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol. Rev. 64: 706-21, 2012. [Journal] |
|
| 7)
Pouliot LM, Chen Y, Bai J, Guha R, Martin SE, Gottesman MM, Hall MD. Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. Cancer Res. [Epub ahead of print], 2012. [Journal] |
|
| 8)
Pluchino KM, Hall MD, Goldsborough AS, Callaghan R, Gottesman MM. Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist. Updat. 15: 98-105, 2012. [Journal] |
|
| 9)
Shaffer BC, Gillet J, Patel C, Baer MR, Bates SE, Gottesman MM. Drug resistance: Still a daunting challenge to the successful treatment of AML. Drug Resist. Updat. 15: 62-69, 2012. [Journal] |
|
| 10)
Rottenberg S, Vollebergh MA, de Hoon B, de Ronde J, Schouten PC, Kersbergen A, Zander SA, Pajic M, Jaspers JE, Jonkers M, Lodén M, Sol W, van der Burg E, Wesseling J, Gillet JP, Gottesman MM, Gribnau J, Wessels L, Linn SC, Jonkers J, Borst P. Impact of Intertumoral Heterogeneity on Predicting Chemotherapy Response of BRCA1-Deficient Mammary Tumors. Cancer Res. 72: 2350-61, 2012. [Journal] |
|
| Click Here to View Expanded Bibliography. |
This page was last updated on 4/10/2013.
